Cancer Diagnostics Market-Rising Prevalence of Cancer & Demand for New Diagnostic Techniques Accelerate the Growth of the Market

Global Cancer Diagnostics Market is predicted to reach USD 269.1 billion at a CAGR of 6.70% during the forecast period:

Market Research Future (MRFR) has published a cooked research report on the “Global Cancer Diagnostics Market” that contains information from 2022 to 2030. The Global Cancer Diagnostics Market is estimated to register a CAGR of 6.70% during the forecast period of 2022 to 2030.

MRFR recognizes the following companies as the key players in the Global Cancer Diagnostics Market— Exact Sciences Corporation, Arquer Diagnostics Ltd, BioMark Diagnostics Inc, Biotheranostics, Agilent Technologies, Thermo Fisher Scientific, Illumina, Becton Dickinson and Company (BD), GE Healthcare, QIAGEN N.V., Abbott Laboratories.

Cancer Diagnostics Market Highlights

Global Cancer Diagnostics Market is accounted to register a CAGR of 6.70% during the forecast period and is estimated to reach USD 269.1 Billion by 2030.

Cancer is a complex disease characterized by the abnormal growth and proliferation of cells, leading to the formation of tumors or the invasion of nearby tissues. Early and accurate diagnosis of cancer is crucial for initiating timely and appropriate treatments, improving patient outcomes, and increasing the chances of successful management and potential cure. Cancer diagnostics typically involve a combination of clinical evaluation, medical imaging, and laboratory tests. Clinical assessment may include a thorough medical history, physical examination, and evaluation of symptoms. Medical imaging techniques such as X-rays, CT scans, MRI scans, ultrasound, or PET scans are used to visualize the internal structures of the body and identify any abnormal growths or tumors.

Segment Analysis

The Global Cancer Diagnostics Market has been segmented based on Type, Application, and End User.

Based on Type, the market is segmented into Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy, and others. The Imaging Testing category dominates the Cancer Diagnostics market due to its ability to visualize and identify tumors or abnormal growths, providing essential information for cancer detection, staging, and treatment planning.

Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer, and others. The Lung Cancer category dominates the Cancer Diagnostics market due to the high prevalence of lung cancer worldwide and the need for accurate and timely diagnosis for effective treatment planning and patient management.

Based on End Users, the market is segmented into Diagnostic Centers, Hospitals and Clinics, Research Institutes, and others. The Diagnostic Centers category dominates the Cancer Diagnostics market due to their specialized infrastructure, advanced diagnostic technologies, and expertise in conducting comprehensive cancer diagnostic tests, facilitating accurate and efficient cancer diagnosis and treatment.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cancer Diagnostics Market Research Report

Regional Analysis

The Global Cancer Diagnostics Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Cancer Diagnostics Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global Cancer Diagnostics Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Global Cancer Diagnostics Market comprises of Middle East, Africa, and Latin America.

In 2021, the North American cancer diagnostics market reached a value of USD 8.4 billion and is projected to exhibit a compound annual growth rate (CAGR) of 42.80% during the study period. This growth is fueled by significant companies undertaking strategic actions in the market.

The Asia Pacific cancer diagnostics market is anticipated to experience significant CAGR growth from 2022 to 2030. This growth can be attributed to strategic moves made by major companies, increased efforts in cervical screening programs to raise awareness and promote screening, rising investments in research and development, and technological advancements.

The Europe cancer diagnostics market holds the second-highest market share in terms of growth rate. The accelerated adoption of preventive diagnostic approaches is a consequence of the government's intensified initiatives to enhance public awareness of cancer. Additionally, the increasing prevalence of breast, lung, and prostate cancer in the region is driving the demand for cancer detection tools.

Key Findings of the Study

• The Global Cancer Diagnostics Market is expected to reach USD 269.1 Billion by 2030, at a CAGR of 6.70% during the forecast period.


• The North America Cancer Diagnostics market reached a value of USD 0.457 billion and is


• The Europe cancer diagnostics market exhibits the second-highest growth rate and is characterized by the rapid adoption of preventive diagnostic methods, driven by the government's efforts to raise public awareness of cancer. Furthermore, the growing incidence of breast, lung, and prostate cancer in the region contributes to the increased demand for cancer detection tools.


• Based on the Type, the Market has been segmented into Imaging Testing holding the largest market in 2022.


• Exact Sciences Corporation, Arquer Diagnostics Ltd, BioMark Diagnostics Inc, Biotheranostics, Agilent Technologies, Thermo Fisher Scientific, Illumina, Becton Dickinson and Company (BD), GE Healthcare, QIAGEN N.V., Abbott Laboratories.